MYOCARDIAL REMODELING RISK FACTORS AT STAGE II-IV CHRONIC KIDNEY DISEASE


Cite item

Full Text

Abstract

Aim. To evaluate frequency and risk factors of development of left ventricular hypertrophy (LVH) of the heart in patients with chronic kidney disease (CKD) of stage II-IV Material and methods. The trial enrolled 83 patients (42 - 51% males, 41 - 49% females, mean age 46.7 years) with stage II-IV CKD of non-diabetic origin. Glomerular filtration rate (GFR) estimated according to Cockroft-Goult formula was 37,7 ml/min (95% confidence interval from 33,9 до 41,4). Chronic renal failure duration averaged 2,7 years (95 % CI from 2.0 to 3.3). Arterial hypertension (AH) was diagnosed in 96% patients, hereditary predisposition to cardiovascular diseases - in 54 %, obesity — in 60 %, lipid disbolism - in 66%, anemia — in 34 % and hyperphosphatemia — in 45 %; 40% patients smoked. Echocardiography was performed in all the patients. Results. LVH was detected in 31 (37.3%) of 83 patients. With progression of renalfailure, frequency of registration of LVH increased. LVH onset was associated with conventional (age, AH, high level of total cholesterol) and renal (lowering of GFR, anemia, hyperphosphatemia) factors. Concentric remodeling, concentric LVH, eccentric LVH were detected in 31.3, 19.3 and 18.1% patients, respectively. Eccentric LVH developed more frequently under the influence of factors associated with renal failure (GFR, anemia, hyperphosphatemia, hypocalciemia). Concentric LVH was characterized with the highest systolic blood pressure. Conclusion. Patients with renal dysfunction develop LVH of different geometric model associated with both conventional and renal risk factors even at early stages of CKD.

About the authors

T E Rudenko

I.M. Sechenov Moscow State Medical University

Email: atatianaer@yandex.ru
канд. мед. наук, ст. науч. сотр. отд. нефрологии

I M Kutyrina

I.M. Sechenov Moscow State Medical University

д-р мед. наук, проф., вед. науч. сотр. отд. нефрологии

M Yu Shvetsov

I.M. Sechenov Moscow State Medical University

канд. мед. наук, вед. науч. сотр. отд. нефрологии

References

  1. Ronco C., Haapio M., House A. et al. Cardiorenal syndrome. J. Am. Coll. Cardiol. 2008; 52 (19): 1527—1539.
  2. Мухин Н. А., Моисеев В. С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестн. РАМН 2003; 11: 50—55.
  3. Levin A., Singer J., Thompson R. et al. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am. J. Kidney Dis. 1996; 27: 347—354.
  4. London G. M., Fabiany F. Left ventricular dysfunction in end-stage renal disease: echocardiographic insights. In: Parfrey P. S., Harnett J. D. (eds.). Cardiac dysfunction in chronic uremia. Boston: Kluwer. 1992; vol. 8: 117—138.
  5. Levy D., Garrison R. G., Savage D. D. et al. Prognostic implication of echocardiographically determined left ventricular mass index in the Framingham Heart Study. N. Engl. J. Med. 1990; 22: 1561—1566.
  6. Glassok R. J., Pecoita-Filho R., Barberato S. H. Left ventricular mass in chronic kidney disease and ESRD. Clin. J. Am. Soc. Nephrol. 2009; 4: S79—S91.
  7. Бадаева С. В., Томилина Н. А., Бикбов Б. Т. и др. Структурнофункциональные изменения миокарда при прогрессирующей хронической почечной недостаточности. Нефрология и диализ. 2006; 8 (3): 232—239.
  8. Шутов А. М., Кондратьева Н. И., Куликова Е. С. др. Влияние межсуточной вариабельности артериального давления на геометрию левого желудочка у больных с додиализной хронической почечной недостаточностью. Тер. арх. 2002; 6: 42—46.
  9. Милованов Ю. С., Козловская Л. В., Милованова Л. Ю. Анемия у больных с хронической болезнью почек: принципы терапии. Качество жизни. Медицина 2006; 4: 90—95.
  10. Мухин Н. А. (ред.). Нефрология: Нац. руководство. М: ГЭОТАР-Медиа; 2009.
  11. Levin A., Singer J., Thompson C. R. et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobine. Am. J. Kidney Dis. 1999; 34: 125—134.
  12. Paoletty E., Bellino D., Cassottana P. et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am. J. Kidney Dis. 2005; 46: 320—327.
  13. Кутырина И. М., Руденко Т. Е., Швецов М. Ю., Кушнир В. В. Роль ремоделирования крупных сосудов в развитии гипертрофии левого желудочка сердца на додиализной стадии хронической почечной недостаточности. Тер. арх. 2008; 6: 37—41.
  14. Achinger S. G., Ayus J. C. Left ventricular hypertrophy is hyperphosphatemia among dialysis patients a risk factor? J. Am. Soc. Nephrol. 2006; 17: S255—S261.
  15. Шутов А. М., Куликова Е. С., Кондратьева Н. И. и др. Гипертрофия левого желудочка сердца у больных в додиализном периоде хронической почечной недостаточности, не связанной с сахарным диабетом. Нефрология 2001; 5 (2): 49—53.
  16. Thuraisigham R. C., Tucker B., Lipkin G. W. et al. Left ventricular hypertrophy in early renal failure. Nephrol. Dial. Transplant. 1994; 7: 859—860.
  17. Eckardt K.-U., Scherhag A., Macdougall I. C. et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J. Am. Soc. Nephrol. 2009; 20: 2651—2660.
  18. Волгина Г. В., Дудаев В. А. Концентрическое ремоделирование миокарда у больных с хронической почечной недостаточностью. Рос. кардиол. журн. 2001; 5: 21—25.
  19. Oberg B. P., McMenamin E., Lucas F. L. et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to serve chronic kidney disease. Kidney. Int. 2004; 17: 229—232.
  20. Matteucci M. C., Wuhl E., Picca S. et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J. Am. Soc. Nephrol. 2006; 17: 218—226.
  21. Moon K. H., Song I. S., Yang W. S. et al. Hypoalbuminemia as a risk factor for progressive left ventricular hypertrophy in hemodialysis patients. Am. J. Nephrol. 2000; 20: 396—401.
  22. Zoccali C., Benedetto F. A., Mallamaci F. et al. Left ventricular mass in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65: 1492—1498.
  23. London G. M., Pannier B., Guerin A.P. et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J. Am. Soc. Nephrol. 2001; 12: 2759—2767.
  24. Paoletti E., Bellino D., Gallina A. M. et al. Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? Nephrol. Dial. Transplant. 2010; 25: 670—677.
  25. Chen S. C., Su H.-M., Hung C.-C. et al. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 2750—2758.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies